3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
7
Terminated
2
Active not recruiting
2
Withdrawn
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Small Cell Lung Carcinoma
9
Ovarian Neoplasms
8
Neuroblastoma
4
Retinoblastoma
3
Fallopian Tube Neoplasms
3
Sarcoma, Ewing
2
Lung Neoplasms
2
Ganglioneuroblastoma
2
Carcinoma, Ovarian Epithelial
2
Brain Neoplasms
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Recurrence
1
Pleuropulmonary blastoma
1
Peritoneal Neoplasms
1
Pediatric Brain Tumor
1
Osteosarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Follicular
1
Leukemia, Myeloid, Acute
1
Glioma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
49
Specimen Handling
29
Magnetic Resonance Spectroscopy
25
Biopsy
25
Radiosurgery
17
Gemcitabine
17
Nivolumab
16
Cyclophosphamide
14
Cisplatin
14
Paclitaxel
13
Carboplatin
13
Bevacizumab
13
Leucovorin
11
Irinotecan
11
Fluorouracil
11
Drug Therapy
11
Taxes
10
Radiotherapy
10
Oxaliplatin
10
Capecitabine
10
trastuzumab deruxtecan
9
fludarabine
9
cemiplimab
8
Doxorubicin
8
Cetuximab
8
abemaciclib
7
Trastuzumab
7
Pemetrexed
7
Fulvestrant
7
Docetaxel
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm Metastasis
×
Topotecan
×
Clear all
NCT07213804
2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3
Recruiting
1,080 enrolled